Industry Trend Analysis - Nuplazid's Potential Makes ACADIA An Acquisition Target - AUG 2017

BMI View: Sales of ACADIA Pharmaceuticals ' sole product, Nuplazid, are growing and will reach the blockbuster level. Whilst it may be some time before the company makes a profit and risk remains, ACADIA is focused on CNS conditions with large unmet need and has a broad clinical development programme, and thus represents a potential acquisition target. Interest may come from Johnson & Johnson, Pfizer, Merck & Co, Allergan, Teva Pharmaceutical Industries, Biogen, Otsuka or Eli Lilly.

US-based ACADIA Pharmaceuticals is a biopharmaceutical company focused on the development and commercialisation of innovative medicines to address unmet medical needs in central nervous system disorders. The CNS is a therapy segment that sees a high rate of interest from companies looking to acquire assets, particularly late-stage ones for diseases with high unmet medical need, and whilst not without risk, ACADIA, which has a current market cap of USD3.61bn (June 26 2017), represents an acquisition target.

Nuplazid Sales Are Rising

Nuplazid Will Be A Blockbuster
Forecast Annual Product Sales (USDmn)
e=estimate. Source: Bloomberg, BMI

This article is part of our Americas coverage. To access this article subscribe now or sign up for free trial